Index. Note: Page numbers of article titles are in boldface type.

Transcription

1 Note: Page numbers of article titles are in boldface type. A Abetalipoproteinemia NASH and, 537 Acquired errors of metabolism NASH and, Amiodarone steatohepatitis due to, 527 Anticonvulsant mood stabilizers in NASH patients, 622 Antidepressant(s) in NASH patients, 621 Antipsychotic agents in NASH patients, Antiretroviral therapy steatohepatitis due to, Apoptosis as Hh signaling amplifier, markers of in noninvasive diagnosis of NASH, 570 Autocrine signaling, 551 B Bacterial overgrowth NASH due to, Ballooning in NASH prognosis, 492 Bariatric surgery in NASH management, Behavioral therapy in NASH management, Benzodiazepine sedatives in NASH patients, 623 Brachial artery flow-mediated vasodilation of NAFLD and, Buspirone in NASH patients, 623 Clin Liver Dis 16 (2012) doi: /s (12) /12/$ see front matter ª 2012 Elsevier Inc. All rights reserved. liver.theclinics.com

2 648 C Cannabis steatohepatitis due to, Canonical signaling, Cardiovascular disease (CVD) NAFLD and biologic mechanisms in, incidence of, mortality associated with, 606 Cardiovascular disease (CVD) markers subclinical NAFLD and, Cardiovascular system NAFLD and, See also Nonalcoholic fatty liver disease (NAFLD), cardiovascular link to Carotid artery ultrasound of, Celiac disease NASH and, 536 Chemotherapy-associated steatohepatitis, 530 Children NAFLD in vs. adults, See also Nonalcoholic fatty liver disease (NAFLD), in children vs. adults Cholinesterase inhibitors in NASH patients, 624 Cirrhosis, 557 Computed tomography (CT) of coronary artery calcifications NAFLD and, 601 in fibrosis assessment in NASH, 580 CT. See Computed tomography (CT) CVD. See Cardiovascular disease (CVD) D DEAEH. See 4,4 0 -Diethylaminoethoxyhexestrol (DEAEH) Diet in NASH management, Dietary factors in hepatic steatosis, ,4 0 -Diethylaminoethoxyhexestrol (DEAEH) steatohepatitis due to, Drug-induced steatohepatitis, amiodarone, 527 antiretroviral therapy, cannabis, chemotherapies, 530 glucocorticoids, 530 methotrexate,

3 649 E perhexiline maleate and DEAEH, prevalence of, 526 tamoxifen, 529 Eating disorders obesity and, Elastography magnetic resonance in fibrosis assessment in NASH, transient in fibrosis assessment in NASH, Enzyme(s) liver as surrogate marker in NAFLD diagnosis, Epigenetics in NAFLD, Exercise in NASH management, 634 F Familial hypobetalipoproteinemia NASH and, 537 Fatty liver disease gut microbiota and, Fibrosis. See Liver fibrosis G Gene(s) in NAFLD, Genetic(s) in hepatic steatosis, in NAFLD, Genetic diseases metabolic diseases and, Glucocorticoids steatohepatitis due to, 530 Glucose homeostasis in hepatic steatosis micro-rna regulation of, Growth hormone deficiency NASH and, Gut microbiota fatty liver disease due to, H HCC. See Hepatocellular carcinoma (HCC) HDL. See High-density lipoprotein (HDL) Hedgehog (Hh) ligands, 551

4 650 Hedgehog (Hh) signaling pathway amplifiers of apoptosis and inflammation, canonical signaling, in HCC dysregulation of, in injured liver activation of, 552 noncanonical signaling, 551 overview of, in repair and regeneration, extracellular matrix, 556 fibrogenesis and fibrogenic repair, 555 growth of progenitor population of cells and epithelial-to-mesenchymal transition response, OPN and fibrogenesis, 556 vascular remodeling, 556 Hepatic steatosis dietary factors in, genetics in, glucose homeostasis in micro-rna regulation of, gut microbiota and, inflammatory factors in, insulin signaling in micro-rna regulation of, mechanisms of, metabolic factors in, transcriptional factors in, Hepatocellular carcinoma (HCC) Hh signaling in dysregulation of, in NASH risk factors for, Hh signaling pathway. See Hedgehog (Hh) signaling pathway High-density lipoprotein (HDL) in CVD link to NAFLD, Histologic scoring systems in prediction of clinically meaningful outcomes in NASH, Hypobetalipoproteinemia familial NASH and, 537 Hypothyroidism NASH and, Hypoxia in NAFLD pathogenesis, I IBD. See Inflammatory bowel disease (IBD) Inborn errors of metabolism NASH and,

5 651 Inflammation as Hh signaling amplifier, Inflammatory bowel disease (IBD) NASH and, Inflammatory factors in hepatic stenosis, Insulin sensitizers in NASH management, Insulin signaling in hepatic steatosis micro-rna regulation of, Intestinal factors NASH associated with, L Lifestyle modification in NASH management, behavioral therapy, dietary recommendations, evidence from controlled trials, 632 evidence from observational studies, exercise, 634 weight loss, 635 Ligand(s) Hh, 551 Lipodystrophy(ies) NASH and, 537 Lipoprotein high-density in CVD link to NAFLD, Lithium in NASH patients, Liver biopsy in NASH diagnosis and staging, 568 limitations of, , Liver disease(s). See also specific diseases pharmacokinetic effects of, Liver enzymes as surrogate marker in NAFLD diagnosis, Liver fat remodeling hypothesis PNPLA3 and, Liver fibrosis in NASH imaging assessment of, CT in, 580 MRE in, MRI in, 580 transient elastography in, prognostic indicators, risk factors for,

6 652 Liver (continued ) serum markers of, direct markers, 576 proprietary predictive panels, simple laboratory tests, with clinical markers, stellate cell and, hit model of, 550 Liver histology in NASH in predicting clinically meaningful outcomes, See also Nonalcoholic steatohepatitis (NASH), clinically meaningful outcomes in, liver histology in prediction of M Magnetic resonance elastography (MRE) in fibrosis assessment in NASH, Magnetic resonance imaging (MRI) in fibrosis assessment in NASH, 580 Mallory-Denk bodies (MDBs) in NASH prognosis, MDBs. See Mallory-Denk bodies (MDBs) Memantine in NASH patients, 624 Mental health obesity and mechanisms linking, 620 Metabolic diseases NASH and, Metabolic factors in hepatic stenosis, Methotrexate steatohepatitis due to, Micro-RNA regulation in hepatic steatosis in insulin signaling and glucose homeostasis, Microbiota gut fatty liver disease due to, Mood/anxiety disorders obesity and, 618 MRE. See Magnetic resonance elastography (MRE) MRI. See Magnetic resonance imaging (MRI) N NAFLD. See Nonalcoholic fatty liver disease (NAFLD) NASH. See Nonalcoholic steatohepatitis (NASH) Nonalcoholic fatty liver disease (NAFLD) cardiovascular link to, biologic mechanisms in, clinical perspective on,

7 HDL in, incidence of, mortality-related, 606 subclinical CVD brachial artery flow-mediated vasodilation in, coronary artery calcifications in CT of, 601 marker for, pulse-wave velocity in, 602 ultrasound of carotid artery in, in children vs. adults, diagnosis, genetics, histology, management, natural history, pathophysiology of, 589 quality of life, described, diagnosis of in children vs. adults, liver enzymes as surrogate marker in, ultrasound as surrogate marker in, epidemiology of genetic, See also Nonalcoholic fatty liver disease (NAFLD), genetic epidemiology of epigenetics in, gene(s) in, genetic architecture of, genetic epidemiology of, beyond DNA sequence variation, described, future challenges related to, joining effects of genetic variants from multiple pathways, next-generation sequencing techniques potential advance generated by, PNPLA3 in, prioritization based on previous reported loci, systems biology approaches, genetic susceptibility to, histology of in children vs. adults, mortality due to CVD and, 606 natural history of in children vs. adults, obesity and, 616. See also Obesity pathogenesis of molecular mediators of, pathophysiology of in children vs. adults,

8 654 Nonalcoholic (continued) prevalence of, 505, quality of life with in children vs. adults, sexual dimorphism of RS variant and, 470 treatment of in children vs. adults, psychiatric drugs in, recommendations for clinical decision making, Nonalcoholic steatohepatitis (NASH) background of, bacterial overgrowth and, celiac disease and, 536 clinically meaningful outcomes in liver histology in prediction of, histologic features in prognostication, , ballooning, fibrosis, 492 MDBs, histologic scoring systems, limitations of, variability in diagnosing individual pathologic lesions, 499 definition of lack of consensus for, 499 described, 488, , diagnosis of liver biopsy in, 568 limitations of, noninvasive, apoptosis markers in, 570 clinical and laboratory variables in, 570 routine imaging studies in, disease progression in fibrosis and stellate cell, 557 mechanisms of, See also specific mechanisms and Hedgehog (Hh) signaling pathway future directions in, repair gone awry, fibrosis in imaging assessment of, See also Liver fibrosis, in NASH, imaging assessment of risk factors for, serum markers of, See also Liver fibrosis, in NASH, serum markers of genetic diseases and, growth hormone deficiency and, HCC in risk factors for, histologic progression of, 488 hypothyroidism and,

9 655 IBD and, intestinal factors in, lipodystrophies and, 537 metabolic diseases and, mortality associated with, all-cause related, cardiovascular-related, liver-related, 497 posttransplant-related, 498 nutritional factors in, 534 pathways to, pharmacokinetic effects of, prevalence of, 488, 505 staging of liver biopsy in, 568 treatment of, bariatric surgery in, future research agenda in, 637 lifestyle modification in, See also Lifestyle modification, in NASH management pharmacologic, psychiatric drugs in anticonvulsant mood stabilizers, 622 antidepressants, 621 antipsychotics, benzodiazepine sedatives, 623 buspirone, 623 cholinesterase inhibitors, 624 interactions between hypolipidemic and psychiatric drugs, 624 lithium, memantine, 624 nonbenzodiazepine sedatives, 623 pharmacokinetic effects, psychostimulants, 623 psychological, in twenty-first century, Noncanonical signaling, 551 Nuclear receptors in NAFLD pathogenesis, Nutritional factors NASH associated with, 534 O Obesity mental health and mechanisms linking, 620 NAFLD and, 616 psychiatric disorders and, See also specific disorders eating disorders, mood/anxiety disorders, 618

10 656 Obesity (continued) relationship between, schizophrenia, psychological and psychiatric management of, weight-loss interventions for, weight-loss programs for suboptimal weight loss and weight regain in, 617 Occupational steatohepatitis, 532 OPN fibrogenesis and, 556 Orlistat in NASH management, 636 P Paracrine signaling, 551 Perhexiline maleate steatohepatitis due to, PNPLA3 gene liver fat remodeling hypothesis and, NAFLD and, sex interaction and, 470 Psychiatric disorders obesity and, See also specific disorders and Obesity, psychiatric disorders and Psychostimulants in NASH patients, 623 Pulse-wave velocity NAFLD and, 602 Q Quality of life NAFLD effects on in children vs. adults, R RS variant in sexual dimorphism of NAFLD, 470 S Sex interaction gene by PNPLA3 and, 470 Steatohepatitis chemotherapy-associated, 530 drug-induced, See also Drug-induced steatohepatitis nonalcoholic. See Nonalcoholic steatohepatitis (NASH) occupational, 532

11 657 Steatosis diagnosis of noninvasive, 569 clinical and laboratory variables in, 569 hepatic mechanisms of, See also Hepatic steatosis Stellate cells liver fibrosis and, 557 T Tamoxifen steatohepatitis due to, 529 Transcriptional factors in hepatic stenosis, Transient elastography in fibrosis assessment in NASH, U Ultrasound of carotid artery, as surrogate marker in NAFLD diagnosis, V Vasodilation flow-mediated of brachial artery NAFLD and, Vitamin E in NASH management, 636 W Weber-Christian disease NASH and, 537 Weight loss interventions for, in NASH management, 635 suboptimal in weight-loss programs, 617 Weight-loss programs suboptimal weight loss and weight regain in, 617 Weight regain in weight-loss programs, 617 Wilson disease NASH and, 536